Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Shaoping Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3364-7110; OpenAlex author ID A5101870898. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 3 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 3 papers

Papers 11

  1. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy. Co-author DOI 10.1016/j.cmet.2025.10.015↗
  2. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Co-author DOI 10.1038/s41556-025-01667-0↗
  3. Targeting MXD1 sensitises pancreatic cancer to trametinib. Co-author DOI 10.1136/gutjnl-2024-333408↗
  4. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  5. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  6. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  7. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  8. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  9. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  10. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  11. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zheng · 11 shared papers, 2021–2025 · strength 1.58
  2. Lingxing Zeng · 11 shared papers, 2021–2025 · strength 1.58
  3. Xudong Huang · 11 shared papers, 2021–2025 · strength 1.58
  4. Jialiang Zhang · 11 shared papers, 2021–2025 · strength 1.58
  5. Dongxin Lin · 11 shared papers, 2021–2025 · strength 1.58
  6. Rufu Chen · 7 shared papers, 2021–2024 · strength 0.88
  7. Jiachun Su · 7 shared papers, 2021–2023 · strength 0.86
  8. Ziming Chen · 5 shared papers, 2023–2025 · strength 0.85
  9. Zilan Xu · 5 shared papers, 2023–2025 · strength 0.85
  10. Chunling Xue · 5 shared papers, 2023–2025 · strength 0.85
  11. Quanbo Zhou · 5 shared papers, 2023–2024 · strength 0.72
  12. Xiaowei He · 4 shared papers, 2023–2025 · strength 0.66
  13. Yanfen Zheng · 5 shared papers, 2021–2023 · strength 0.58
  14. Rui Li · 4 shared papers, 2023–2024 · strength 0.58
  15. Ying Ye · 4 shared papers, 2021–2023 · strength 0.47
  16. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  17. Junge Deng · 4 shared papers, 2021–2023 · strength 0.44
  18. Zhixiang Zuo · 3 shared papers, 2021–2023 · strength 0.38
  19. Xiaoyu Wu · 2 shared papers, 2025 · strength 0.38
  20. Lusheng Wei · 3 shared papers, 2021 · strength 0.29
  21. Xu Che · 2 shared papers, 2021 · strength 0.19
  22. Chen Hsuan Wu · 2 shared papers, 2021 · strength 0.19
  23. Ling Pan · 2 shared papers, 2021 · strength 0.19
  24. Rufu Chen · 1 shared paper, 2023 · strength 0.14
  25. Chengfeng Wang · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.